GB0403600D0 - Methods and reagents for treating disease - Google Patents
- ️Wed Mar 24 2004
GB0403600D0 - Methods and reagents for treating disease - Google Patents
Methods and reagents for treating diseaseInfo
-
Publication number
- GB0403600D0 GB0403600D0 GBGB0403600.0A GB0403600A GB0403600D0 GB 0403600 D0 GB0403600 D0 GB 0403600D0 GB 0403600 A GB0403600 A GB 0403600A GB 0403600 D0 GB0403600 D0 GB 0403600D0 Authority
- GB
- United Kingdom Prior art keywords
- reagents
- methods
- treating disease
- disease
- treating Prior art date
- 2004-02-18 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01205—IMP dehydrogenase (1.1.1.205)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0403600.0A GB0403600D0 (en) | 2004-02-18 | 2004-02-18 | Methods and reagents for treating disease |
PCT/GB2005/000626 WO2005079815A2 (en) | 2004-02-18 | 2005-02-17 | Methods and reagents for treating autosomal dominant diseases of the eye |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0403600.0A GB0403600D0 (en) | 2004-02-18 | 2004-02-18 | Methods and reagents for treating disease |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0403600D0 true GB0403600D0 (en) | 2004-03-24 |
Family
ID=32039955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0403600.0A Ceased GB0403600D0 (en) | 2004-02-18 | 2004-02-18 | Methods and reagents for treating disease |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0403600D0 (en) |
WO (1) | WO2005079815A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021817A2 (en) | 2004-08-23 | 2006-03-02 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated introacular pressure by sirnas |
TWI386225B (en) | 2004-12-23 | 2013-02-21 | Alcon Inc | Rnai inhibition of ctgf for treatment of ocular disorders |
TWI401316B (en) * | 2004-12-23 | 2013-07-11 | Alcon Inc | Rnai inhibition of serum amyloid a for treatment of glaucoma |
TW200639253A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
KR20080018858A (en) | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | RNA-mediated inhibition of fleece-related protein for the treatment of glaucoma |
GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
ES2750125T3 (en) | 2012-09-05 | 2020-03-25 | Sylentis Sau | SiRNA and its use in methods and compositions for the treatment and / or prevention of eye conditions |
WO2015132303A1 (en) | 2014-03-04 | 2015-09-11 | Sylentis Sau | Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions |
EP4012035B1 (en) * | 2014-09-16 | 2024-11-06 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
EP3194601B1 (en) * | 2014-09-16 | 2021-10-27 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
WO2016044478A1 (en) * | 2014-09-16 | 2016-03-24 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9519299D0 (en) * | 1995-09-21 | 1995-11-22 | Farrar Gwyneth J | Genetic strategy |
US20030224516A1 (en) * | 2002-06-03 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of prox-1 expression |
WO2004022782A2 (en) * | 2002-09-04 | 2004-03-18 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
WO2004094636A1 (en) * | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
-
2004
- 2004-02-18 GB GBGB0403600.0A patent/GB0403600D0/en not_active Ceased
-
2005
- 2005-02-17 WO PCT/GB2005/000626 patent/WO2005079815A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2005079815A3 (en) | 2006-04-27 |
WO2005079815A2 (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216080A1 (en) | 2016-10-14 | Compositions and methods for treating or preventing oxalate-related disease |
IL182837A0 (en) | 2008-04-13 | Methods, assays and compositions for treating retinol-related diseases |
IL175818A0 (en) | 2006-10-05 | Method for treating adamts-5- associated disease |
IL182011A0 (en) | 2007-07-24 | Treatment screening methods |
HK1156274A1 (en) | 2012-06-08 | Devices for carrying out and diagnosing microarray experiments |
IL183059A0 (en) | 2007-10-31 | Cancer treatment method |
GB0403600D0 (en) | 2004-03-24 | Methods and reagents for treating disease |
GB0427821D0 (en) | 2005-01-19 | Catalyst and process |
EP1755394A4 (en) | 2009-08-05 | Cancer treatment method |
IL179359A0 (en) | 2007-03-08 | Cancer treatment method |
PT1611890E (en) | 2009-09-29 | Methods for assessing and treating cancer |
IL183702A0 (en) | 2007-09-20 | Difluoronucleosides and process for preparation thereof |
EP1812850A4 (en) | 2009-03-25 | Efficient multiprocessor system and methods thereof |
EP1765344A4 (en) | 2009-12-02 | Cancer treatment method |
GB0414233D0 (en) | 2004-07-28 | Analysis method |
GB0424552D0 (en) | 2004-12-08 | Methods and means |
EP1809276A4 (en) | 2009-06-17 | Treatment method |
GB0403847D0 (en) | 2004-03-24 | Methods and means |
EP1802617A4 (en) | 2010-12-15 | Cancer treatment method |
GB0408156D0 (en) | 2004-05-19 | Process and compounds |
GB0421911D0 (en) | 2004-11-03 | Methods and means |
GB0520405D0 (en) | 2005-11-16 | Biological agents and method |
EP1773406A4 (en) | 2008-09-03 | Method for screening agents against human prostate disease |
GB0507963D0 (en) | 2005-05-25 | Composition and method for treating disease |
GB0522732D0 (en) | 2005-12-14 | Composition and method for treating disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
2005-09-07 | AT | Applications terminated before publication under section 16(1) |